

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma, mediastinal B-cell lymphoma and follicular lymphoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation on the draft scope, a consultee stated that '*Therapy, at least initially, is likely to be carried out in a limited number of centres so equality of access for patients across the country will be important*'.

During the scoping workshop the clinical expert stated that axicabtagene ciloleucel would be given to patients at transplant centres, which are well distributed across England.

It was therefore agreed that this was not a valid equalities issue.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This is not considered to be an equalities issue that needs to be addressed by committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable

4. Have any additional stakeholders related to potential equality issues

Technology Appraisals: Scoping

Equality impact assessment for the STA of axicabtagene ciloleucel for treating diffuse large B-cell lymphoma, mediastinal B-cell lymphoma and follicular lymphoma Issue date: December 2017

been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified.

Approved by Associate Director (name): Helen Knight

Date: 07/12/2017